Visterra Obtains $13,000,000 Series A Financing

  • Feed Type
  • Date
    11/9/2012
  • Company Name
    Visterra
  • Mailing Address
    One Kendall Square Cambridge, MA 02139
  • Company Description
    Visterra, Inc. is dedicated to the discovery and development of innovative products for the prevention, treatment and diagnosis of infectious diseases. The Company focuses on technologies that can interrogate how pathogens interact with human cells, a critical first step in the disease process. The company’s lead programs are focused on seasonal and pandemic influenza.
  • Website
    http://www.visterrainc.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $13,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds will be used to further develop and validate Visterra’s technology platform and advance its proprietary infectious disease product pipeline. The company’s lead product candidate, VIS410, is a broad spectrum antibody for the prevention and treatment of both seasonal and pandemic influenza.
  • M&A Terms
  • Venture Investor
    Bill & Melinda Gates Foundation
  • Venture Investor
    Omega Funds

By posting a comment, you agree to our terms and conditions.